PTPRC and neoplasm: Quantitative analysis of the percentage of CD45+ tumor cells expressing CD38 in each condition revealed a highly significant decrease in the cells treated with αCD38 antibody (p < 0.0001 by an unpaired t test) (Fig. 2D).